Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (1-10 of 303) with videos related to

Pageof 31
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 27, 2018
Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer"Jong-Mu Sun
The Korean Journal of Thoracic and Cardiovascular Surgery|August 15, 2020
Adjuvant Therapy for Esophageal Squamous Cell CarcinomaJong-Mu Sun
Current Opinion in Oncology|January 14, 2017
Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?Jong-Mu Sun, Keunchil Park
The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi|August 27, 2004
[Gastrointestinal carcinoid tumor]Jong-Mu Sun, Hyun Chae Jung
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitorSehhoon Park, Joungho Han, Jong-Mu Sun
BMC Medical Imaging|June 4, 2026
Prognostic value of [<sup>18</sup>F]fluorodeoxyglucose PET/CT in esophageal cancer patients treated with anti-PD-1 inhibitorsWonseok Whi, Jong-Mu Sun, Joon Young Choi, et al.
Clinical Medicine Insights. Oncology|June 30, 2012
The effectiveness of maintenance pharmacotherapies for non-small cell lung cancerMyung-Ju Ahn, Jong-Mu Sun, Jin Sock Ahn, et al.
Biomedicines|October 26, 2024
Randomized Phase II Cancer Clinical Trials to Validate Predictive BiomarkersBaoshan Zhang, Jong-Mu Sun, Myung-Ju Ahn, et al.
Cancer Immunology, Immunotherapy : CII|October 30, 2020
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effectJiyun Lee, Binnari Kim, Hyun Ae Jung, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2011
Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapyJong-Mu Sun, Joungho Han, Jin Seok Ahn, et al.
Pageof 31

Showing results (1-10 of 303) with videos related to

Sort By:
Pageof 31
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 27, 2018
Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer"Jong-Mu Sun
The Korean Journal of Thoracic and Cardiovascular Surgery|August 15, 2020
Adjuvant Therapy for Esophageal Squamous Cell CarcinomaJong-Mu Sun
Current Opinion in Oncology|January 14, 2017
Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?Jong-Mu Sun, Keunchil Park
The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi|August 27, 2004
[Gastrointestinal carcinoid tumor]Jong-Mu Sun, Hyun Chae Jung
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitorSehhoon Park, Joungho Han, Jong-Mu Sun
BMC Medical Imaging|June 4, 2026
Prognostic value of [<sup>18</sup>F]fluorodeoxyglucose PET/CT in esophageal cancer patients treated with anti-PD-1 inhibitorsWonseok Whi, Jong-Mu Sun, Joon Young Choi, et al.
Clinical Medicine Insights. Oncology|June 30, 2012
The effectiveness of maintenance pharmacotherapies for non-small cell lung cancerMyung-Ju Ahn, Jong-Mu Sun, Jin Sock Ahn, et al.
Biomedicines|October 26, 2024
Randomized Phase II Cancer Clinical Trials to Validate Predictive BiomarkersBaoshan Zhang, Jong-Mu Sun, Myung-Ju Ahn, et al.
Cancer Immunology, Immunotherapy : CII|October 30, 2020
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effectJiyun Lee, Binnari Kim, Hyun Ae Jung, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2011
Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapyJong-Mu Sun, Joungho Han, Jin Seok Ahn, et al.
Pageof 31